NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/26/2026
Back to search
Official data from USPTO
A
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
43
Latest update
05/26/2026
Trademark type
Combined
Nice classes
5, 42, 45
Filing date
05/04/2023
Registration date
05/26/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/26/2026
Last transaction
05/26/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
2014-02-00
First use in commerce
2014-02-00
Drawing code
3
Owner type
03
Owner location
Vancouver, B.C., CA
Examiner
SIRIGNANO, EMMA MARIE
Law office
M40
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a circle with an "A" inside, with the horizontal line of the "A" having been replaced by a dot.
Holders and representatives
Holders
Acuitas Therapeutics, Inc.
Representatives
Karen Won Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo P.C.
Technical classification
Nice Classes
Class 5Class 42Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparationsdrug delivery agents in the nature of lipid nanoparticle carriers that facilitate delivery of pharmaceutical preparations and nucleic acid therapeutics as pharmaceutical preparations; pharmaceutical preparations comprised of nucleic acidsmessenger RNA and lipid nanoparticles for treating cancergenetic disordersinfectious diseasescardiovascular diseasesliver diseasesautoimmune disordersneurological disordersmetabolic disorders; pharmaceutical preparationsvaccines for human use for treating cancerinfectious diseasescardiovascular diseasesliver diseasesautoimmune disordersneurological disordersmetabolic disordersgenetic disordersallergy; pharmaceutical preparations for gene silencingfor gene editingfor antibody therapeuticsfor protein replacement therapeuticsfor nucleic acid therapeuticsfor treating cancergenetic disordersinfectious diseasescardiovascular diseasesliver diseasesautoimmune disordersneurological disordersmetabolic disorders
Class 42
Researchdevelopmentevaluation services in the fields of pharmaceuticalsmedical therapiesimmunologyvaccinesbiotechnologynanotechnologygene therapylipidslipid formulationslipid nanoparticlesnucleic acidsmessenger RNAdrug delivery agentsnucleic acid therapeuticssynthetic chemistry process technology; synthetic chemistry servicesdesignsynthesisanalysisevaluationbiophysical characterization of lipidslipid formulationslipid nanoparticles; preclinical study servicesconducting scientific feasibility studiespharmacodynamic and pharmacokinetic studiesscientific feasibility studies as to the human safety and tolerability studies regarding clinical pathology and histopathologyimmune response characterization studiesbioanalytical services in the fields of pharmaceuticalsmedical therapiesimmunologyvaccinesbiotechnologynanotechnologygene therapylipidslipid formulationslipid nanoparticlesnucleic acidsmessenger RNAdrug delivery agentsnucleic acid therapeutics; scientific clinical research servicesin the fields of chemical molecular analysispharmaceutical product optimizationconducting clinical trial services for others in the field of pharmaceuticals; research and development of new formulation products for othersvaccines and nucleic acid therapeutics; research and development for others in the fields of new pharmaceuticalsmedical therapiesvaccinesgene therapiesdrug delivery agentsnucleic acid therapeutics for others; project management services for scientific research and development programs in the fields of pharmaceuticalsmedical therapiesimmunologyvaccinesbiotechnologynanotechnologygene therapylipidslipid formulationslipid nanoparticlesnucleic acidsmessenger RNAdrug delivery agentsnucleic acid therapeuticssynthetic chemistry process technology; consultancy services in the fields of scientific research and development of pharmaceuticalsmedical therapiesimmunologyvaccinesbiotechnologynanotechnologygene therapylipidslipid formulationslipid nanoparticlesnucleic acidsmessenger RNAdrug delivery agentsnucleic acid therapeuticssynthetic chemistry process technology
Class 45
Regulatory compliance consultancy services in the fields of pharmaceuticalsmedical therapiesimmunologyvaccinesbiotechnologynanotechnologygene therapylipidslipid nanoparticlesnucleic acidmessenger RNAdrug delivery agentsnucleic acid therapeuticssynthetic chemistry process technology
Publications
History of USPTO decisions and trademark events.
43 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
05/26/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
05/02/2026
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
05/02/2026
SUPC
STATEMENT OF USE PROCESSING COMPLETE
04/08/2026
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
04/08/2026
DOCK
ASSIGNED TO EXAMINER
01/24/2026
IUAF
USE AMENDMENT FILED
10/17/2025
EISU
TEAS STATEMENT OF USE RECEIVED
10/17/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04/22/2025
EX1G
SOU EXTENSION 1 GRANTED
04/22/2025
EXT1
SOU EXTENSION 1 FILED
04/22/2025
EEXT
SOU TEAS EXTENSION RECEIVED
04/22/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/17/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
12/17/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
12/17/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
12/17/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
12/17/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
10/22/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/18/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/18/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/18/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/27/2024
PUBO
PUBLISHED FOR OPPOSITION
08/27/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/07/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/18/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
07/18/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
07/18/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
07/18/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
07/18/2024
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
05/12/2024
GNFR
FINAL REFUSAL E-MAILED
05/12/2024
CNFR
FINAL REFUSAL WRITTEN
05/12/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/16/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/16/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/16/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/26/2024
GNRT
NON-FINAL ACTION E-MAILED
01/26/2024
CNRT
NON-FINAL ACTION WRITTEN
01/26/2024
DOCK
ASSIGNED TO EXAMINER
01/26/2024
MDSM
NOTICE OF DESIGN SEARCH CODE E-MAILED
06/03/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/02/2023
NWAP
NEW APPLICATION ENTERED
05/08/2023
Continuous trademark protection
Get notified about every new filing that threatens A or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.